Trial Profile

Phase 1/2 Study of TSN1611 in Subjects with Advanced Solid Tumors Harboring KRAS G12D Mutation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TSN 1611 (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Tyligand Bioscience

Most Recent Events

24 May 2024 According to a Tyligand Bioscience media release, the company plans to initiate enrollment in China in the coming months.
24 May 2024 According to a Tyligand Bioscience media release, The program has been cleared for IND by U.S. FDA and China NMPA in Feb and April 2024, respectively.
24 May 2024 According to a Tyligand Bioscience media release, the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com